Recruiting Liver Cancer Studies in Orange
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic...
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new trea...
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced soli...
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
The primary objectives of Cohort A Phase 1b are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unrese...
Combination of TATE and PD-1 Inhibitor in Liver Cancer
This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint...
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepa...
About Liver Cancer Clinical Trials in Orange
Liver cancer most commonly presents as hepatocellular carcinoma (HCC) and is often associated with chronic liver disease or hepatitis. It is one of the fastest-growing causes of cancer death. Treatment options include surgery, liver transplant, ablation, and systemic therapies.
There are currently 6 liver cancer clinical trials recruiting participants in Orange, CT. These studies are seeking a combined 1,700 participants. Research is being sponsored by AbbVie, Hoffmann-La Roche, AstraZeneca and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Liver Cancer Clinical Trials in Orange — FAQ
Are there liver cancer clinical trials in Orange?
Yes, there are 6 liver cancer clinical trials currently recruiting in Orange, CT. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Orange?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Orange research site will contact you about next steps.
Are clinical trials in Orange free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Orange studies also compensate for your time and travel.
What liver cancer treatments are being tested?
The 6 active trials in Orange are testing new therapies including novel drugs, biologics, and treatment approaches for liver cancer.
Data updated March 2, 2026 from ClinicalTrials.gov